Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NC-MSC is an induced pluripotent stem cell (iPSC)-derived mesenchymal stem cell (iMSC) therapy being developed by NovoCare in partnership with Factor Bioscience. By utilizing iPSCs as a starting material, the program aims to overcome the limitations of traditional donor-derived MSCs, such as limited scalability and donor-to-donor variability, providing a more consistent and potent therapeutic product. NC-MSC is designed to exert anti-inflammatory and tissue-repair effects through the secretion of various paracrine factors and direct cellular interactions. It is currently being investigated for the treatment of Acute Respiratory Distress Syndrome (ARDS) and Elomas Syndrome, with development progressing through preclinical and IND-enabling stages.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NC-MSC.